FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine. Disclosed are: a pharmaceutical composition for the treatment of hypertriglyceridemia and mixed dyslipidemia, comprising EPA (eicosapentaenoic acid) in a weight percentage of 50 to 60%; DHA (docosahexaenoic acid) in a weight percentage of 17 to 23%; DPA (docosapentaenoic acid, 22: 5 n-3) in a weight percentage of 1 to 8%, wherein at least 90% by weight of the polyunsaturated acid in the composition is present in the form of a free acid; a unit dosage form - a capsule for oral administration of said composition and methods for treating hypertriglyceridemia using same (versions).
EFFECT: technical result: significant increase in the bioavailability of the claimed composition in healthy adults (an increase in the EP: AA ratio in blood plasma) compared to a single dose of compositions with ethyl omega-3 acid available on the market.
19 cl, 56 dwg, 40 tbl
